Optimizing Biotechnology State Economic Development Post-COVID

The U.S. biotechnology industry has weathered several economic downturns but the COVID pandemic has uniquely placed significant strains on not only on health services but also state budgets.

That, in turn, has challenged public officials to strategically review the measures historically in place to support our industry in a variety of ways ranging from capital for emerging companies, R&D tax credits, bioenergy research, and workforce credits for manufacturing companies.
 
As CSBA state associations begin to address the immediate economic needs of their member companies resulting from the pandemic, it is a time to rethink and elevate strategic planning to cultivate a future roadmap that retains and grows economic opportunity.